Overview
- Editors:
-
-
Elie Azoulay
-
Service de Réanimation Médicale, Hôpital Saint Louis, Paris, France
Detailed, up-to-date information is provided on all relevant aspects of pulmonary involvement in patients with hematological malignancies
Leading experts discuss epidemiology, diagnostic strategy, lung infections, non-infectious pulmonary involvement, and treatment, including decision making in patients with acute respiratory failure
Invaluable "pearls" relating to each condition are presented
Includes supplementary material: sn.pub/extras
Access this book
Other ways to access
Table of contents (73 chapters)
-
-
Preamble and Introduction
-
-
-
-
-
Epidemiology
-
-
-
- Carlos Agustí, Carmen Lucena, Antoni Torres
Pages 47-55
-
-
-
-
- Aarif Y. Khakoo, Callie S. Kwartler
Pages 87-115
-
- Benoit Guery, Karine Faure
Pages 117-119
-
Diagnostic Strategy in HM Patients
-
Front Matter
Pages 121-121
-
Diagnostic Strategy In HM Patients
-
- Alexandre Boyer, Didier Gruson
Pages 123-129
-
-
- Christophe Dooms, Vincent Ninane
Pages 147-153
-
- Cédric de Bazelaire, Raphael Calmon, Marion Chapelier, Amélie Pluvinage, Eric de Kerviler
Pages 155-173
-
- Laurent Camous, Virginie Lemiale, Achille Kouatchet, David Schnell, Sandra de Miranda, Élie Azoulay
Pages 175-189
-
- Michael G. Alexandrakis, Paschalis Steiropoulos, Demosthenes Bouros
Pages 191-208
About this book
The number of patients treated for hematological malignancies is increasing steadily. To maximize cure rates, aggressive treatments have been introduced, including high-dose chemotherapy, stem cell transplantation, and targeted therapies. As a result, overall and disease-free survival rates have improved substantially, but at the price of life-threatening toxic and infectious complications that chiefly target the lung. This book provides clinicians caring for patients with hematological malignancies with detailed, up-to-date information on all relevant aspects of pulmonary involvement. Individual sections are devoted to epidemiology, diagnostic strategy, lung infections, non-infectious pulmonary involvement, and treatment, including decision making in patients with acute respiratory failure. Each of these sections contains a number of chapters, all written by leading international experts. In addition, the reader’s attention is drawn to important "pearls" relating to each condition.
Reviews
From the reviews:
“This is a detailed, multiauthored review of infectious, inflammatory, and thromboembolic complications in patients with a variety of hematological cancers. … Practitioners with an interest in hematological malignancy and intensivists providing critical care resources for management of these patients are an appropriate audience for this work coming from an international panel of authors, the majority of whom are from France. … This unique book effectively reviews the current therapy, incidence, and outcomes for this complex patient group.” (David J. Dries, Doody’s Review Service, December, 2011)
Editors and Affiliations
-
Service de Réanimation Médicale, Hôpital Saint Louis, Paris, France
Elie Azoulay
About the editor
Dr Élie Azoulay is the Assistant Director of the Medical ICU at the Saint-Louis Teaching Hospital, Paris, France. He is a professor of medicine at the Denis Diderot Paris 7 University. From his background as a pulmonologist, Dr Azoulay developed a strong research focus on acute respiratory failure in immunocompromized patients. His PhD work was on respiratory physiology in an experimental model of cancer chemotherapy-related pulmonary toxicity. He has several published clinical research studies on acute respiratory failure in hematology and oncology patients. Also, Dr Azoulay leads a collaborative multicenter group that has performed observational studies, large cohort studies, and randomized controlled trials in cancer patients with ARF. His second major field of interest in clinical research is communication with family members of ICU patients. He constituted a research group in 1997 (the French Famirea Study Group) to evaluate the ability of critical care clinicians to provide effective information to ICU patients and families. Several of his published studies investigated the burden of critical illness in relatives and in ICU clinicians. The group’s major aim is to identify targets for improvement and to test potential interventions in international RCTs in order to advance ICU practices in the field of information and communication. In addition to clinical and research activities, Dr Azoulay teaches pulmonary medicine, critical care medicine, and ethics at the Paris Medical School. He is also associate editor of Intensive Care Medicine, in the editorial board of the American Journal of respiratory and Critical Care medicine, and the chairman of the ethics section of the ESICM. Dr Azoulay is a member of the European board of Pfizer and Gilead.
